Diagnostics company SphingoTec GmbH (“SphingoTec”) announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic…
German University Hospital Uniklinik RWTH Aachen and diagnostics company SphingoTec GmbH today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and…
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the first published data (1) on the biomarker DPP3 that can predict the evolution of organ function and survival in septic patients.…
Diagnostics company SphingoTec GmbH announced today that two distinct processes are involved in the development of septic shock and that SphingoTec’s biomarkers for endothelial function (vascular…
SphingoTec GmbH (“SphingoTec”) announced today that the Acute Disease Quality Initiative (ADQI) recommends the use of novel biomarkers for AKI, including functional biomarkers as penKid®.
The Uniklinik RWTH Aachen (“Uniklinik RWTH Aachen”) has successfully translated the collaboration for research and biomarker validation with SphingoTec GmbH (“SphingoTec”) into clinical routine.
BHR Pharmaceuticals Ltd (“BHR”) and SphingoTec GmbH (“SphingoTec”) today announced that they have signed a distribution agreement for the commercialization of SphingoTec’s portfolio of diagnostics…
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the publication of first data, proving that its real-time kidney function biomarker penKid® is a reliable biomarker for the…
